A novel compound to selectively protect normal tissues from chemotherapy

Information

  • Research Project
  • 8058518
  • ApplicationId
    8058518
  • Core Project Number
    R43CA137933
  • Full Project Number
    1R43CA137933-01A2
  • Serial Number
    137933
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    9/24/2010 - 14 years ago
  • Project End Date
    3/23/2012 - 12 years ago
  • Program Officer Name
    HAIM, TODD E
  • Budget Start Date
    9/24/2010 - 14 years ago
  • Budget End Date
    3/23/2012 - 12 years ago
  • Fiscal Year
    2010
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    9/24/2010 - 14 years ago

A novel compound to selectively protect normal tissues from chemotherapy

DESCRIPTION (provided by applicant): The successful treatment of human cancer depends on the ability to find treatments that kill tumor cells without impacting normal tissue significantly. An alternative approach is to selectively protect normal tissue from the toxic effects of chemotherapy while leaving the tumor cells vulnerable. Perscitus Biosciences, LLC has successfully synthesized a compound that we hypothesize will increase the protective molecule glutathione in normal tissue but not tumor tissue. Glutathione is known to protect against reactive oxygen species including those generated during the treatment of cancer with chemotherapy. In this project, we will examine the ability of the compound to selectively increase glutathione levels in normal tissue - and not tumor tissue - to protect against chemotherapy- induced toxicity. Analytic methods will be developed in conjunction with the Ohio State University Comprehensive Cancer Center Pharmacoanalytic Laboratory to allow us to measure the different metabolic steps that this compound must undergo to generate glutathione. If successful, this compound could significantly decrease much of the toxicity seen with common chemotherapy treatments of cancer. Importantly, protection of the normal tissue will allow escalation of the doses used in cancer treatment, potentially improving the ability to treat cancer effectively. PUBLIC HEALTH RELEVANCE: Over 500,000 people die from cancer in the U.S. each year. To improve the treatment of cancer, treatment regimens are needed with improved tolerability and effectiveness. The compound presented in this project has the potential to both decrease the side effects associated with cancer treatment as well as improve the anti-cancer effect.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    147830
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:147830\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PERSCITUS BIOSCIENCES, LLC
  • Organization Department
  • Organization DUNS
    790953868
  • Organization City
    MADISON
  • Organization State
    WI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    537042587
  • Organization District
    UNITED STATES